相关实验视频
Updated: Jun 5, 2025

10:42
A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
Published on: February 27, 2019
9.4K
基于的抑制剂和纳米颗粒:阿尔茨海默病的新兴治疗方法
Solmaz Mojarad-Jabali1, Kyung-Ho Roh2
1Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
International journal of pharmaceutics
|December 9, 2024
概括
新的抑制剂通过向粉样β,蛋白和金属离子来治疗阿尔茨海默病 (AD) 是有前途的. 纳米粒子增强传递,改善稳定性和潜在的AD疗法的脑透.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,影响全球数百万人,其特点是认知能力下降和记忆力丧失.
- 目前针对粉样β (Aβ) 的阿尔茨海默病治疗方法的有效性有限,需要探索替代治疗策略.
- 研究正在转向其他AD标志,如陶蛋白和大脑金属离子.
研究的目的:
- 审查针对阿尔茨海默病的新兴基于的抑制剂,向Aβ,蛋白和金属离子.
- 评估纳米粒子 (NP) 在克服抑制剂向大脑传递限制方面的潜力.
- 提供对阿尔茨海默症新型治疗方法的全面概述.
主要方法:
- 关于阿尔茨海默病的抑制剂和纳米粒子输送系统的最新研究的文献综述.
- 对针对Aβ,tau蛋白和金属离子的治疗策略的分析.
- 对性质的评估,包括选择性,毒性,半衰期和血脑屏障 (BBB) 透.
主要成果:
- 基于的抑制剂显示出对AD目标的高选择性和低毒性.
- 纳米粒子提供了增强的稳定性,有针对性的传递,并改善了抑制剂的BBB透率.
- 新兴体显示出缓解AD症状和预防神经元损失的潜力.
结论:
- 抑制剂代表了阿尔茨海默病的有希望的治疗途径.
- 纳米颗粒介导的输送显著提高了抑制剂的疗效和脑向.
- 对NP递送的进一步研究可能会导致AD的有效治疗方法,解决未满足的临床需求.
相关概念视频
Alzheimer's Disease: Treatment
163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Alzheimer's Disease: Overview
447
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
447
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96

